PURE Bioscience (OTCMKTS:PURE) and Butterfly Network (NYSE:BFLY) Critical Analysis

Butterfly Network (NYSE:BFLY) and PURE Bioscience (OTCMKTS:PURE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Butterfly Network and PURE Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.66%	-22.80%
PURE Bioscience	-109.59%	N/A	-321.74%

Analyst Ratings

This is a summary of current ratings and target prices for Butterfly Network and PURE Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1	1	3	0	2.40
PURE Bioscience	0	0	0	0	0.00

Butterfly Network presently has a consensus price target of $5.56, indicating a potential downside of 21.48%. Given Butterfly Network’s stronger consensus rating and higher probable upside, research analysts plainly believe Butterfly Network is more favorable than PURE Bioscience.

Institutional & Insider Ownership

37.9% of Butterfly Network shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by insiders. Comparatively, 35.6% of PURE Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Butterfly Network and PURE Bioscience”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61 million	18.48	-$77.06 million	($0.30)	-23.61
PURE Bioscience	$2.20 million	3.78	-$2.40 million	($0.03)	-2.13

PURE Bioscience has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than PURE Bioscience, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Butterfly Network has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, PURE Bioscience has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

Summary

Butterfly Network beats PURE Bioscience on 9 of the 14 factors compared between the two stocks.

About Butterfly Network

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

About PURE Bioscience

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.